Long-Term Persistence of COVID-Induced Hyperglycemia: A Cohort Study.

Publication date: Feb 13, 2024

Although the short-term mortality of patients with COVID-19 infection and hyperglycemia has been well documented, there is little available data regarding longer-term prognosis. The presence of diabetes has not only influenced disease severity but has also impacted its transmission dynamics. In this study, we followed a historical cohort of patients without previous history of diabetes who presented with moderate to severe COVID-19 and were found to have hyperglycemia (random blood glucose > 140 mg/dL) at the time of admission. We evaluated the need for antidiabetic therapy in these patients at the end of 6 months and the risk factors associated with persistent hyperglycemia determined by monthly values of self-monitored blood glucose. Of the seventy participants who were followed telephonically, 54 (77%) continued to receive antidiabetic therapy or have persistent hyperglycemia (> 140 mg/dL) at the end of 6 months. Persistent hyperglycemia at the end of follow-up, was found to be associated with a higher blood glucose at presentation.

Concepts Keywords
Covid Antidiabetic
Diabetes Blood
Glucose Cohort
Monthly Covid
Therapy Diabetes
Dl
End
Found
Glucose
Hyperglycemia
Mg
Persistent
Study
Term
Therapy

Semantics

Type Source Name
disease MESH Hyperglycemia
disease MESH COVID-19
disease MESH infection
disease IDO history
disease IDO blood
drug DRUGBANK Dextrose unspecified form
disease VO time
disease VO monthly

Original Article

(Visited 1 times, 1 visits today)